Refractory pemphigus vulgaris successfully treated with ofatumumab

Systemic therapy targeting CD20, such as rituximab, is a valuable first-line therapeutic option for moderate-to-severe pemphigus vulgaris (PV).1 However, for patients with PV who experience side effects (such as infusion reactions including anaphylaxis) or loss of treatment response to rituximab, this presents a challenging clinical situation. A prior report described a patient with severe PV, who experienced a serum sickness-like reaction with rituximab, achieving complete clinical clearance with durable response using off-label ofatumumab.